tbuckley/cabot-search huggingface dataset:
Update on a phase (ph) 2 study of bortezomib in patients (pts) with relapsed or refractory indolent or aggressive non-Hodgkin's lymphomas (NHL)
Authors: A. Goy, A. Younes, P. McLaughlin, B. Pro, J. Romaguera, F. Hagemeister, L. Fayad, E. G. Trehu, D. Schenkein, M. A. Rodriguez
Journal: Journal of Clinical Oncology (2004)

6581 Background: Proteasome inhibition disrupts many cell cycle checkpoints and pathways that lead to apoptosis. Preclinical and ph 1 studies suggested the proteasome inhibitor bortezomib (VELCADE™, Vc) was active in lymphoma. Methods: The primary objective of this ph 2 study was to document the response rate (RR) and toxicity of Vc in pts with relapsed or refractory NHL. Pts ≥ 16 yr, with relapsed or refractory mantle cell (MCL, gp A) or other B cell lymphomas (gp B) were eligible. Pts received Vc 1.5 mg/m2 IV on d1, 4, 8 and 11 q21d, were restaged q2 cycles, and treated for up to 6 cycles unless removed from study. Results:45 pts: 32 males, 13 females, median age 60 yr (range 45–81), were enrolled. There were 25 pts in gp A and 20 pts in gp B, including 10 diffuse large cell lymphoma (DLCL), 4 follicular lymphoma (FL), 3 transformed (t) FL, 2 small lymphocytic lymphoma (SLL), 1 Waldenström's macroglobulinemia (WM). Gp A had 3 median prior therapies (range 1–6); gp B had 4 (range 1–12). In gp A, of 21 evaluable (ev) pts, there were 11 responders: 3 CR, 1 CRu (unconfirmed CR), and 7 PR (RR = 52.3%), 2 MR, 2 no change (NC), 6 POD (progression of disease). Mean DOR (duration of response) was 5.7 mo (1.2–15 mo). In gp B, there were 8 ev DLCL with 1 PR (DOR 4 mo), 1 NC, 6 POD; 4 ev FL with 2 MR, 1 NC, 1 POD; 1 ev tFL with POD; 2 ev SLL with 1 NC, 1 POD; 1 WM pt had PR. Grade 3/4 toxicities were GI (5 pts), hypotension/fatigue (6 pts), neuropathy (1 pt with prior vinca/taxanes), and pneumonia (2 pts); hematologic toxicities were neutropenia (8) (only 1 pt with ANC <500) and thrombocytopenia (14 pt) (only 1 pt with platelets <10; most entered with platelets <30–50). 2 patients died: 1 had Cryptococcus meningitis, 1 had generalized zoster with encephalitis. Conclusions: This study showed remarkable activity of Vc in MCL and encouraging results in other B cell lymphomas. Future studies will include combinations of Vc with other chemotherapy and/or biological agents. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Millennium Pharmaceuticals, Inc. Millennium Pharmaceuticals, Inc. Millennium Pharmaceuticals, Inc.
Abstract 80: Observations of End-Tidal Co2 and Invasive Cardiac Output Measurements During Mechanical CPR in a Porcine Model of Cardiac Arrest
Authors: R Di Maio, P Crawford, H Hartley, D Brody, L Farley, Jmcc Anderson, Aaj Adgey
Journal: Circulation (2010)

Introduction: A number of physiological indicators were explored to determine if ICG amplitude could be used as a determinant of effective CPR to guide lay responders in administering optimized cardiac massage thereby improving survival rates from out of hospital cardiac arrest. Methods: A total of seven porcine models around 52.8+/-9kg were used. End-tidal CO2 (ETCO2), Cardiac Output (CO), Carotid Flow and the Impedance Cardiogram (non-invasive measure of cardiac output) were utilized as a basis for detecting the presence of effective CPR. Ethical approval was granted by the Northern Ireland Home Office. Models were anaesthetised using Propofol and Isoflurane and connected to a Datex Ohmeda(R) monitor. Carotid flow and coronary perfusion pressure were measured via the carotid and thermodilution via the jugular. Recordings from each experiment were acquired using HEM(R) Notocord software for analysis. Results: ETCO2 levels averaged 23.3 mmHg during CPR compared to the models who did not receive CPR producing values close to of 3+/-1mmHg. Cardiac Output values of >22% of the normal CO were achieved which, reported as adequate for ROSC. Carotid Flow increased with depth of CPR. ICG amplitude increased with CO as did ETCO2. The results show that the physiological parameters used were good indicators of CPR efficacy. Conclusions: These findings are potentially significant in the field of resuscitation. An algorithm will incorporate the results from this study, providing feedback to the operator on the quality of CPR by measuring the ICG amplitude which can be correlated to the basic physiological parameters recorded during this study. (C) 2010 American Heart Association, Inc.
Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: The impact of the addition of rituximab to CHOP chemotherapy
Authors: D. Villa, K. J. Savage, L. H. Sehn, J. Connors
Journal: Journal of Clinical Oncology (2007)

8037 Background: The addition of rituximab to CHOP (CHOP-R) chemotherapy improves outcome in patients with diffuse large B- cell lymphoma (DLBCL). However, limited data suggests that it may not impact the risk of central nervous system (CNS) relapse. We evaluated the risk of CNS relapse and associated predictive factors in a large population-based cohort of patients with DLBCL. Methods: All patients with DLBCL diagnosed from September 1, 1999 to January 14, 2005 at the British Columbia Cancer Agency were identified, including those from a recently published report (Sehn, J Clin Onc. 2005). Patients were included if they were ≥16 years old with advanced stage (stage III /IV, or stage I /II with B symptoms or bulky disease (≥10 cm)), or limited stage with testicular involvement and excluded if HIV-positive or known to have CNS involvement at diagnosis. From Sept 1999 to Feb 2001 patients were treated with CHOP- type chemotherapy. After March 1, 2001 patients received CHOP-R. Results: A total of 435 patients with DLBCL were identified; 125 (29%) were treated with CHOP and 310 (71%) with CHOP-R. There were 28 CNS relapses with no significant difference in frequency between CHOP-treated (11 (9%)) or CHOP-R-treated (17 (5%)) patients (p=0.202). The median time to CNS relapse (8.1 mos vs 6.7 mos) and median survival after CNS relapse (2.7 mos vs 3.8 mos, p=0.665) were similar in the CHOP and CHOP-R treated patients, respectively. In univariate analysis, testicular involvement, renal involvement, advanced stage, and LDH ≥2x ULN were associated with increased risk of CNS relapse. In a multivariate analysis, testicular (OR 7.44, p=0.013) or renal (OR 6.23, p=0.012) involvement, and stage IV disease (OR 4.43, p=0.034) were independent predictors of CNS relapse. Conclusions: Consistent with prior reports, the addition of rituximab does not appear to significantly influence the risk of CNS relapse in patients with DLBCL, possibly due to poor CNS penetration. Risk factors for CNS relapse in the rituximab era are similar to those noted in prior reports based on anthracycline-treated patients. The overall survival of patients with CNS relapse is dismal and new strategies to reduce its incidence warrant further evaluation. No significant financial relationships to disclose.
Dermoscopy, a useful tool for general practitioners in melanoma screening: a nationwide survey
Authors: P. Chappuis, G. Duru, O. Marchal, P. Girier, S. Dalle, L. Thomas
Journal: British Journal of Dermatology (2016)

Dermoscopy improves diagnostic accuracy in melanoma, as shown by several meta-analyses. Although it is used by general practitioners (GPs) in Australia, Canada and Italy, no published data on this topic are available in France.To review the opinions and use of dermoscopy by GPs in France and to understand their practice of skin examination.We designed a descriptive and cross-sectional survey and conducted it between 26 November and 26 December 2014. An anonymous, multiple-choice questionnaire about the demographic characteristics, skin examination modalities and use and training in dermoscopy was sent to 4057 GPs in four large regions of France. Pearson, χ(2) , Student, Welch and Fisher tests were used for cross-tabulation statistical analysis.Only 8% of respondents had access to a dermoscope; most were male practitioners and aged > 50 years. Dermoscopy increased self-confidence in analysing pigmented lesions (P = 0·004), and dermoscopy users referred fewer patients to dermatologists. The number of biopsies was reduced in the dermoscopy users group (P = 0·004). In total, 425 questionnaires were returned and analysed. Dermoscopy users took more time to evaluate a single pigmented lesion (P = 0·015). Only 16·9% of physicians declared having received some training on dermoscopy, yet this number reached 47% for those owning a dermoscope. Their training was mostly short and recent. Overall 29·2% of the respondents said the main advantage was to reduce the number of referrals to the dermatologists (P = 0·004), while its main disadvantage was the necessity of training (54·6%). Our responders declared they could spend seven working days on a dermoscopy training course.Our study demonstrates positive opinions regarding dermoscopy, despite a minority of French GPs using this technique in the areas surveyed. The need for formal training appears to be the main limitation to wider use. Appropriate and specifically designed training programmes should be offered.
Operable benign meningioma patients appear to have expected survival that is equivalent to a normal United States population
Authors: S. Soyuer, E. L. Chang, U. Selek, M. H. Maor, F. Demonte
Journal: Journal of Clinical Oncology (2004)

1543 Background: To compare survival from benign meningioma undergoing resection, with the expected survival from a normal United States population. Materials and Methods: Our patient series consisted of 92 patients with histologically verified benign meningioma (WHO grade I) operated on The University of Texas M. D. Anderson Cancer Center between March 1953 and January 2001. The median age was 48 years (range, 17–93 years), and there was a 2.2 (63/29) preponderance of female patients. The 5 most common tumor sites in descending order was convexity, falx, sphenoid wing, cavernous sinus, and clivus. . Forty-eight patients underwent gross total resection, and 44 patients underwent subtotal resection. Forty patients underwent adjuvant (n=12) or salvage radiotherapy (n=28). The endpoints analyzed were progression-free survival (PFS) and overall survival (OS). PFS and OS rates were calculated using the Kaplan-Meier method. Overall survival curve of the study population is compared with the age, race, and sex-adjusted expected survival curve for the U.S. Population born in 1970, generated from data obtained from the U.S. Department of Health and Human Services. Results: With a median follow-up of 7.7 years, there were 17 deaths and 44 recurrences in the study population. The 15-year PFS and OS rates for all patients were 33% and 70%, respectively. Superimposition of the the study survival data demonstrates that the age-adjusted expected survival curve for the U.S. Population born in 1970 lies within the confidence intervals for overall survival curve of the study population. Conclusion: This finding suggests that operable meningioma patients at a single institution do not exhibit any greater risk of mortality than that which would be expected for the normal U.S. population. No significant financial relationships to disclose.
Abstract 11752: Home Blood Pressure Variability or Instability is not Therapeutic Target During Anti-hypertensive Treatment: the Japan Morning Surge-Target Organ Protection (J-TOP) study
Authors: Satoshi Hoshide, Yuichiro Yano, Shimizu Motohiro, Kazuo Eguchi, Joji Ishikawa, Kazuomi Kario
Journal: Circulation (2012)

Introduction: Home BP monitoring has been recognized and widely adopted. Not only mean home BP but also day-by-day BP variability or instability is associated with target organ damage (TOD) and car...
Reversible immortalisation, human artificial chromosomes, and induced pluripotency: new gene and cell therapy technologies for Duchenne muscular dystrophy
Authors: Sara Benedetti, Hidetoshi Hoshiya, Narumi Uno, Giulia Ferrari, Yasuhiro Kazuki, Sara Maffioletti, Tamara Casteels, Martina Ragazzi, Graziella Messina, Francesco Muntoni, Mitsuo Oshimura, Giulio Cossu, Francesco Saverio Tedesco
Journal: The Lancet (2016)
Randomized Italian multicentric trial comparing cisplatinum and gemcitabine with or without low dose interleukin-2 (IL-2) in advanced non-small cell lung cancer (NSCLC)
Authors: R. Ridolfi, M. Dall’agata, O. Bertetto, A. Santo, E. Naglieri, M. Lopez, F. Recchia, P. Lissoni, G. Porcile, L. Fumagalli, O. Nanni
Journal: Journal of Clinical Oncology (2005)

7139
Comparative effectiveness of everolimus (EVE) and axitinib (AXI) for second-line treatment of metastatic renal cell carcinoma (mRCC) in the United States: A retrospective chart review.
Authors: Nicholas J. Vogelzang, Sumanta Kumar Pal, James E. Signorovitch, William M. Reichmann, Pooja Chopra, Zhimei Liu, Jose Ricardo Perez, Eric Jonasch
Journal: Journal of Clinical Oncology (2015)

500 Background: EVE and AXI are approved as 2 nd -line TTs for mRCC. This study compares OS and PFS among mRCC patients treated with EVE and AXI following 1 st TKI. The extent to which the duration of 1 st TKI can inform optimal selection of a 2 nd -line TT is of interest. Methods: A retrospective patient chart review study was conducted. Medical oncologists or hematologists/oncologists who treated ≥3 mRCC patients in the past year were recruited from a national panel. Patient eligibility criteria included: 1) aged ≥18 years; 2) initiated and discontinued 1 st TKI (sunitinib or pazopanib) for medical reasons; 3) initiated 2 nd TT between 2/1/2012 and 1/31/2013. OS was defined as time from initiation of 2 nd TT to death. PFS was defined as time from initiation of 2 nd TT to physician/chart reported progression or death, whichever occurred first. Multivariable Cox proportional hazards models were used to estimate the hazard ratio (HR) for OS and PFS between EVE and AXI, adjusting for age, gender, type and duration of 1 st TKI, response to 1 st TKI, duration of mRCC at 2 nd TT, disease profile, performance status, sites of metastases, and years of physician practice. Comparative effectiveness was also analyzed by the type and duration (&lt;6, 6-12, &gt;12 months) of 1 st TKI. Results: A total of 298 and 122 patients received 2 nd TT with EVE and AXI. After adjusting for baseline characteristics, there was no statistically significant difference between EVE and AXI in OS [HR (95% CI): 1.10 (0.69-1.75)] or PFS [HR (95% CI): 1.12 (0.81-1.54)]. When stratified by subgroups defined by type and duration of 1 st TKI, there was no statistically significant difference in OS between EVE and AXI in all subgroups, except for patients with &lt;6 months on sunitinib as 1 st TKI in which AXI had longer OS (HR =3.95). There was no statistically significant difference in PFS between EVE and AXI in all subgroups. Conclusions: In this large, retrospective chart review study, there was no significant difference in OS or PFS between EVE and AXI. Subgroup analyses stratified by duration of 1 st TKI did not suggest that longer duration of 1 st TKI was associated with better efficacy for 2 nd -line AXI vs. EVE.
Evaluating Chemotherapy at the End of Life—Reply
Authors: Holly G. Prigerson, Alfred I. Neugut, Paul K. Maciejewski
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Pathologic features after radical perineal prostatectomy in potential candidates for active monitoring
Authors: P. de Geeter, S. Schaefers, H. Loehmer, P. Albers
Journal: Journal of Clinical Oncology (2008)

16091 Background: When counseling patients about treatment options, it is useful to know the results of immediate surgical treatment in potential candidates for active monitoring. Methods: Prospective analysis of a contemporary series of 135 radical perineal prostatectomies (RPP). RPP in our department is strictly confined to patients with cT1c, PSA ≤ 10 ng/ml and Gleason sum ≤ 7, provided primary Gleason is 3. 45 patients (33 %) were potential candidates (group 1) for active monitoring: PSA < 10 ng/ml, exclusion of Gleason score 4, only 1 or 2 positive cores of at least 8 (each < 50%). 18 patients (13%) were optimal candidates (group 2) with only 1 positive core out of 10. Mean PSA was 6,8 (± 2) in group 1 and 7 (± 2,1) ng/ml in group 2. Unfavorable pathological features were defined as: Gleason sum ≥ 7 and/or extracapsular extension (ECE or ≥ pT3a) and/or positive margins (PM). Bad pathology includes: Gleason sum > 7 and/or ECE and/or PM. Results: ECE (predominantly pT3a) was found in 8/45 (17,8%) of potential candidates (group 1) for active monitoring and in 3/18 (16,6%) of patients, considered optimal candidates (group 2). Two thirds of the patients had ultimately pT2c disease in both groups. There were no patients with Gleason sum 8, but 31% in group 1 and 55 % in group 2 revealed a Gleason 7 on final pathology. PM rate was 16% in group 1 and 11% in group 2. The overall PM rate was 10% in all RPP patients with pT2c disease. 49% of group 1 and 61% of group 2 presented unfavorable pathologic features. Bad pathology was present in 29% of group 1 and in 22% of group 2. Conclusions: It remains difficult to define potential candidates for active monitoring, using the presently available criteria (PSA level, biopsy Gleason, number and extent of positive cores). Disease is more extensive (≥ pT2c) in over two thirds of those selected patients, revealing unfavorable pathology in 49 - 61% and bad pathology (ECE and/or PM) in 22–29% of the patients. As there is considerable evidence that those adverse pathologic features are associated with worse long-term outcomes, improvement of clinical staging is necessary with close histopathological follow up if active surveillance is considered. No significant financial relationships to disclose.
Spectral-Domain Optical Coherence Tomography Imaging in 67 321 Adults
Authors: Praveen J. Patel, Paul J. Foster, Carlota M. Grossi, Pearse A. Keane, Fang Ko, Andrew Lotery, Tunde Peto, Charles A. Reisman, Nicholas G. Strouthidis, Qi Yang
Journal: Ophthalmology (2015)
Induction of Malignant Melanomas Associated With Fibrosarcomas in Gnotobiotic Cats Inoculated With Gardner-Feline Fibrosarcoma Virus&lt;xref ref-type="fn" rid="FN2"&gt;2&lt;/xref&gt;
Authors: B McCullough, J Schaller, J A Shadduck, D S Yohn
Journal: JNCI Journal of the National Cancer Institute (1972)
Measurement of the Angina Threshold Using Atrial Pacing: A New Technique for the Study of Angina Pectoris
Authors: G. E. Sowton, R. Balcon, D. Cross, M. H. Frick
Journal: Cardiovascular Research (1967)

A threshold level of tension-time index has been found in patients with angina pectoris above which angina occurred. End-diastolic x-ray films showing an increase, rather than the usual decrease, in heart size with increasing rate were thought to explain the absence of a threshold level in some patients.
Isolation and Characterization of a Cell Line From the Cocultivation of Lucké Renal Tumor Cells and Nontransformed Feeder Cells 2 3
Authors: Louis S. Kucera, Janice Simonson
Journal: JNCI Journal of the National Cancer Institute (1974)

The in vitro cocultivation of renal adenocarcinoma (Lucké tumor) cells with a feeder layer of frog tongue cells at 28° C successfully yielded 2 newly established cell lines. Data on the morphology,growth characteristics, and karyology of these cells strongly suggested that the established cell lines (LT-1 and LT-2) originated from the Lucké tumor. LT-1 cells transplanted into the anterior eye chamber of Rana pipiens proliferated like transformed or neoplastic cells. Eosinophilic and Feulgenpositive intracytoplasmic inclusion bodies were detected in LT-1 cells. Electron microscopic studies showed that inclusion bodies contained cell components and irregular structures of varying sizes and shapes but no intact Lucké herpesvirus (LHV) particles. Treatment of LT-1 cells with 5-bromodeoxyuridine and 5-iododeoxyuridine did not induce LHV multiplication.
Targeted Anti-Anticoagulants
Authors: Kenneth A. Bauer
Journal: New England Journal of Medicine (2015)

Four direct oral anticoagulants have been approved for use in many countries. These drugs are valuable alternatives to vitamin K antagonists, such as warfarin, for many patients requiring anticoagulation to prevent stroke due to nonvalvular atrial fibrillation and to treat and prevent venous thromboembolism. The mechanism of these agents is to selectively inhibit either thrombin or factor Xa, which are critical enzymes in the common pathway of blood coagulation. Dabigatran etexilate inhibits thrombin, whereas apixaban, edoxaban, and rivaroxaban inhibit factor Xa.Direct oral anticoagulants have several pharmacologic advantages over vitamin K antagonists, including a wider therapeutic window, a rapid onset . . .